Inflammatory cytokine production induced by an analogue of muramyl dipeptide MDP-LYS(l18) in rat macrophage cultures and dog synovial fluid

Inflammation

Volumn 20, Issue 1, 1996, Pages 43-56

  Sugawara, Tadaki ^a   Takada, Sanae ^a   Miyamoto, Megumi ^a   Nomura, Mamoru ^a   Kato, Michiyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLONY STIMULATING FACTOR; CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 8; LEUKOTRIENE B4; MURAMYL DIPEPTIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BIOASSAY; CELL CULTURE; CONTROLLED STUDY; DIALYSIS; DOG; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN PURIFICATION; RAT; SYNOVIAL FLUID; SYNOVITIS; SYNOVIUM;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANIMALS; ARTHRITIS; BENZOQUINONES; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; COLONY-STIMULATING FACTORS; CULTURE MEDIA, CONDITIONED; CYCLOHEXIMIDE; CYTOKINES; DOGS; GENE EXPRESSION REGULATION; INTERLEUKIN-1; INTERLEUKIN-8; LIPOXYGENASE INHIBITORS; MACROPHAGES, PERITONEAL; MALE; NEUTROPHILS; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; STIMULATION, CHEMICAL; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; CANIS FAMILIARIS;

EID: 0030024187     PISSN: 03603997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01487744     Document Type: Article

References (51)

1. ELLOUZ, F., A. ADAM, R. CIORBARU, and E. LEDERER. 1974. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59:1317-1325.
2. NAKAJIMA, R., Y. ISHIDA, F. YAMAGUCHI, T. OTANI, Y. ONO, M. NOMURA, T. UNE, and Y. OSADA. 1988. Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice. Arzneim.-Forsch./Drug Res. 38(II):986-992.
3. TSUBURA, E., T. NOMURA, H. NIITANI, S. OSAMURA, T. OKAWA, M. TANAKA, K. OTA, H. NISHIKAWA, T. MASAOKA, M. FUKUOKA, A. HORIUCHI, K. FURUSE, M. ITO, K. NAGAI, T. OGURA, M. KOZURU, N. HARA, K. HARA, M. ICHIMARU, and K. TAKATSUKI. 1988. Restorative activity of muroctasin on leukopenia associated with anticancer treatment. Arzneim.-Forsch./ Drug Res. 38(II):1070-1074.
4. SUGAWARA, T., M. KATO, and S. TAKAYAMA. 1992. Arthritis and hematological changes induced by an analogue of muramyl dipeptide in rats. Fund. Appl. Toxicol. 18:395-404.
5. ONO, Y., T. IWASAKI, M. SEKIGUCHI, and T. ONODERA. 1988. Subacute toxicity of muroctasin in mice and dogs. Arzneim.-Forsch./Drug Res. 38(II):1024-1027.
6. SUGAWARA, T., S. TAKADA, K. FURUHAMA, S. TAKAYAMA, M. NOMURA, and M. KATO. 1995. Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats. Int. J. Exp. Path. 76:191-199.
7. AKASAKI, M., H. MASAYASU, W. TSUKADA, and T. TAKEGOSHI, 1988. Specific binding sites of muroctasin on murine macrophages. Arzneim.-Forsch./Drug Res. 38(II):978-980.
8. AZUMA, I., and T. OTANI. 1994. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans. Med. Res. Rev. 14:401-414.
9. AREND, W. P., and J.-M. DAYER. 1990. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33:305-315.
10. BRENNAN, F. M. 1994. Role of cytokines in experimental arthritis. Clin. Exp. Immunol. 97:1-3.
11. 2 production by 12-O-tetradecanoylphorbol 13-acetate (TPA)-type and non-TPA-type tumor promoters in macrophages and its inhibition by cycloheximide. Biochem. Biophys. Acta 834:42-47.
12. ISCOVE, N. N., J. S. SENN, J. E. TILL, and E. A. MCCULLOCH. 1971. Colony formation by normal and leukemic human marrow cells in culture: Effect of conditioned medium from human leukocytes. Blood 37:1-5.
13. SUGAWARA, T., M. MIYAMOTO, S. TAKAYAMA, and M. KATO. 1995. Separation of neutrophils from blood in human and laboratory animals and comparison of the chemotaxis. J. Pharmacol. Toxicol. Method 33:91-100.
14. AKASAKI, M. T. TAKASHI, Y. KITA, and W. TSUKADA. 1987. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18). Agent Action 22:144-150.
15. SHIMODA, K., S. OKAMURA, N. HARADA, F. OMORI, and Y. NIHO. 1990. Production of interleukin-6 from macrophages by MDP-LyS(L18), romurtide. Res. Commun. Chem. Pathol. Pharmacol. 70:289-296.
16. NAKAJIMA, R., Y. ISHIDA, K. AKAHANE, M. SEKIGUCHI, and Y. OSADA. 1991. Stimulatory effect of romurtide on hematopoiesis in monkeys. Arzneim.-Forsch./Drug Res. 41(I):60-65.
17. SHIMODA, K., S. OKAMURA, C. KAWASAKI, F. OMORI, T. MATSUGUCHI, and Y. NIHO. 1990. Muroctasin [MDP-Lys(L18)] augments the production of granulocyte colony-stimulating factor (G-CSF) from human peripheral blood mononuclear cells in vitro. Int. J. Immunopharmac. 12:729-735.
18. AKAHANE, K., F. YAMAGUCHI, Y. KITA, T. UNE, and Y. OSADA. 1990. Stimulation of macrophages by muroctasin to produce colony-stimulating factors. Arzneim.-Forsch./Drug Res. 40(I):179-183.
19. FONTANA, A., H. HENGARTNER, E. WEBER, K. FEHR, P. J. GROB, and G. COHEN. 1982. Interleukin 1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol. Int. 2:49-53.
20. WESTACOTT, C. I., J. T. WHICHER, I. C. BARNES, D. THOMPSON, A. J. SWAN, and P. A. DIEPPE. 1990. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann. Rheum. Dis. 49:676-681.
21. YOCUM, D. E., L. ESPARZA, S. DUBRY, J. B. BENJAMIN, R. VOLZ, and P. SCUDERI. 1989. Characteristics of tumor necrosis factor production in rheumatoid arthritis. Cell. Immunol. 122:131-145.
22. HOPKINS, S. J., and A. MEAGER. 1988. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Clin. Exp. Immunol. 73:88-92.
23. WILLIAMSON, D. J., C. G. BEGLEY, M. A. VADAS, and D. METCALF. 1988. The detection and initial characterization of colony-stimulating factors in synovial fluid. Clin. Exp. Immunol. 72:67-73.
24. Xu, W. D., G. S. FIRESTEIN, R. TAETLE, K. KAUSHANSKY, and N. J. ZVAIFLER. 1989. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J. Clin. Invest. 83:876-882.
25. SAKLATVALA, J., S. J. SARSFIELD, and Y. TOWNSEND. 1985. Pig interleukin 1: Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever. J. Exp. Med. 162:1208-1222.
26. 2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162:2163-2168.
27. GOWEN, M., D. D. WOOD, E. J. IHRIE, M. K. B. MCGUIRE, and R. G. G. RUSSELL. 1983. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306:378-380.
28. THOMSON, B. M., G. R. MUNDY, and T. J. CHAMBERS. 1987. Tumor necrosis factors α and β induce osteoblastic cells to stimulate osteoclastic bone resorption. J. Immunol. 138:775-779.
29. PETTIPHER, E. R., G. A. HIGGS, and B. HENDERSON. 1986. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. U.S.A. 83:8749-8753.
30. HENDERSON, B., and E. R. PETTIPHER. 1989. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: Evidence for synergistic interactions between cytokines in vivo. Clin. Exp. Immunol. 75:306-310.
31. VAN DE LOO, A. A. J., O. J. ARNTZ, and W. B. VAN DEN BERG. 1992. Flare-up of experimental arthritis in mice with murine recombinant IL-1. Clin. Exp. Immunol. 87:196-202.
32. STIMPSON, S. A., F. G. DALLDORF, I. G. OTTERNESS, and J. H. SCHWAB. 1988. Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide. J. Immunol. 140:2964-2969.
33. HOM, J. T., A. M. BENDELE, and D. G. CARLSON. 1988. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice. J. Immunol. 141:834-841.
34. KILLAR, L. M., and C. J. DUNN. 1989. Interleukin-1 potentiates the development of collagen-induced arthritis in mice. Clin. Science 76:535-538.
35. COOPER, W. O., R. A. FAVA, C. A. GATES, M. A., CREMER, and A. S. TOWNES. 1992. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clin. Exp. Immunol. 89:244-250.
36. KATO, Y., J. IKEGAMI, M. YAMAMOTO, M. MORIWAKI, N. SHIGEMOTO, T. ISHITO, T. NAGANUMA, Y. MATAKI, T. HARA, and T. DEGUCHI. 1991. Repeated dose toxicity of marograstgim (KW-2228): Subcutaneous administration to rats for 13 weeks. Oyo Yakuri/Pharmacometrics (Jpn) 41:499-537.
37. AREND, W. P. 1993. Interleukin-1 receptor antagonist. Adv. Immunol. 54:167-227.
38. SYMONS, J. A., J. A. EASTGATE, and G. W. DUFF. 1990. A soluble binding protein specific for interleukin 1β is produced by activated mononuclear cells. Cytokine 2:190-198.
39. BARRERA, P., A. M. T. BOERBOOMS, E. M. JANSSKN, R. W. SAUERWEIN, H. GALLATI, J. MULDER, T. DE BOO, P. N. M. DEMACKER, L. B. A. VAN DE PUTTE, and J. W. M. VAN DER MEER. 1993. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 36:1070-1079.
40. AREND, W. P., and J.-M. DAYER. 1995. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38:151-160.
41. FORD-HUTCHTNSON, A. W., M. A. BRAY, M. V. DOIG, M. E. SHIPLEY, and M. J. H. SMITH. 1980. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286:264-265.
42. OPPENHEIM, J. J., C. O. C. ZACHARIAE, N. MUKAIDA, and K. MATSUSHIMA. 1991. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Ann. Rev. Immunol. 9:617-648.
43. WATANABE, K., S. KINOSHITA, and H. NAKAGAWA. 1989. Purification and characterization of cytokine-induced neutrophil chemoattractant produced by epithelioid cell line of normal rat kidney (NRK-52E cell). Biochem. Biophys. Res. Commun. 161:1093-1099.
44. BRENNAN, F. M., C. O. C. ZACHARIAE, D. CHANTRY, C. G. LARSEN, M. TURNER, R. N. MAINI, K. MATSUSHIMA, and M. FELDMANN. 1990. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur. J. Immunol. 20:2141-2144.
45. KOCH, A. E., S. L. KUNKEL, J. C. BURROWS, H. L. EVANOFF, G. K. HAINES, R. M. POPE, and R. M. STRIETER. 1991. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J. Immunol. 147:2187-2195.
46. FORREST, M. J., G. J. EIERMANN, R. MEURER, L. A. WALAKOVITS, and D. E. MACINTYRE. 1992. The role of CD18 in IL-8 induced dermal and synovial inflammation. Br. J. Pharmacol. 106:287-294.
47. ENDO, H., T. AKAHOSHI, A. NISHIMURA, M. TONEGAWA, K. TAKAGISHI, S. KASHIWAZAKI, K. MASTUSHIMA, and H. KONDO. 1994. Experimental arthritis induced by continuous infusion of IL-8 into rabbit knee joints. Clin. Exp. Immunol. 96:31-35.
48. PEVERI, P., A. WALZ, B. DEWALD, and M. BAGGIOLINI. 1988. A novel neutrophil-activating factor produced by human mononuclear phagocytes. J. Exp. Med. 167:1547-1559.
49. DJEU, J. Y., K. MATSUSHIMA, J. J. OPPENHEIM, K. SHIOTSUKI, and D. K. BLANCHARD. 1990. Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8. J. Immunol. 144:2205-2210.
50. 2-terminal amino acid sequence identity with melanoma growth stimulatory activity. J. Exp. Med. 171:1091-1100.
51. WOLPE, S. D., and A. CERAMI. 1989. Macrophage inflammatory proteins 1 and 2: Members of a novel superfamily of cytokines. FASEB J. 3:2565-2573.